Valuation: Mazorro Resources Inc.

Market Cap 9.22M 7.97M 7.48M 6.81M 12.8M 882M 12.98M 87.71M 34.33M 442M 34.63M 33.88M 1.47B P/E 2020
-1.43x
P/E 2021 -1.33x
Enterprise Value 7.45M 6.43M 6.04M 5.5M 10.33M 712M 10.48M 70.84M 27.72M 357M 27.97M 27.36M 1.19B EV / Sales 2020
-
EV / Sales 2021 -
Free-Float
100%
Yield 2020 *
-
Yield 2021 -
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - -
Chief Operating Officer - 2019-10-31
Director TitleAgeSince
Chairman 65 2021-05-27
Director/Board Member 70 2020-09-16
Director/Board Member - 2021-05-27
Change 5-day change 1-year change 3-year change Capi.($)
-0.46%-1.89%-11.01%-6.99% 13.24B
-0.16%-2.40%-32.52%-57.64% 4.98B
-0.81%-3.56%+2.32%-3.16% 4.91B
+0.29%+0.12%+7.12%-28.17% 4.2B
-0.03%-2.74%-18.37%+0.58% 3.59B
+0.20%-2.29%-5.07%+13.86% 3.4B
-1.06%-6.37%-8.56%-9.04% 3.35B
+1.19%+0.94%-12.60%-15.53% 2.49B
0.00%+10.60%+3.45%-10.45% 1.81B
Average -0.09%-0.25%-8.36%-12.95% 4.66B
Weighted average by Cap. -0.23%-1.31%-9.61%-13.15%

Financials

2020 2021
Net sales - -
Net income -26.48M -22.87M -21.47M -19.55M -36.73M -2.53B -37.26M -252M -98.53M -1.27B -99.4M -97.24M -4.22B -52.18M -45.06M -42.31M -38.52M -72.38M -4.99B -73.43M -496M -194M -2.5B -196M -192M -8.32B
Net Debt -501K -432K -406K -370K -695K -47.85M -705K -4.76M -1.86M -23.98M -1.88M -1.84M -79.8M -1.77M -1.53M -1.44M -1.31M -2.46M -170M -2.5M -16.87M -6.6M -84.99M -6.66M -6.52M -283M
Logo Mazorro Resources Inc.
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.
Employees
-